View : 26 Download: 0
Biocompatible nanoparticles intercalated with anticancer drug for target delivery: Pharmacokinetic and biodistribution study
- Biocompatible nanoparticles intercalated with anticancer drug for target delivery: Pharmacokinetic and biodistribution study
- Choi S.-J.; Oh J.-M.; Choy J.-H.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Journal of Nanoscience and Nanotechnology
- vol. 10, no. 4, pp. 2913 - 2916
- SCI; SCIE; SCOPUS
- We have developed new hybrid systems consisting of anticancer drugs such as methotrexate (MTX) or 5-fluorouracil (5-FU) and two-dimensional inorganic delivery carrier like layered double hydroxide (LDH). Such an inorganic vector with biocompatible metal ions can be used to overcome toxicity, immunogenecity and poor integration capacity, which are critical problems caused by conventional viral vectors, cationic liposomes and polymers. Moreover, the intercellular mechanism of LDH nanoparticles is primarily related to clathrin-mediated endocytosis, resulting in effective delivery and eventually enhancing drug efficacy. In this report, the effect of LDH intercalated with 5-Fu (5-FuLDH) was evaluated in whole animal by studying pharmacokinetic behavior and tissue distribution. The results showed that 5-Fu-LDH exhibited favorable blood clearance profiles compared to free 5-Fu, such as sustained drug release, prolonged drug half-life, and increased drug accumulation in target tumor tissue. Furthermore, LDH nanoparticles were rapidly excreted from the body and not accumulated in the organs after administration as 5-Fu-LDH. Therefore, the hybrid system can be promising anticancer chemotherapy agent for tumor targeting with biocompatibility. Copyright © 2010 American Scientific Publishers All rights reserved.
- Appears in Collections:
- 자연과학대학 > 화학·나노과학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.